Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.
Checkpoint Therapeutics, Inc. (CKPT) generates frequent news as a commercial-stage immunotherapy and targeted oncology company focused on solid tumor cancers. Company updates center on its FDA-approved product UNLOXCYT™ (cosibelimab-ipdl) for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or curative radiation, as well as on its investigational EGFR inhibitor olafertinib (formerly CK-101).
News items commonly include regulatory milestones such as FDA acceptance and review of the Biologics License Application (BLA) for cosibelimab, issuance of a complete response letter related to a third-party contract manufacturing organization, BLA resubmission, and eventual FDA approval of UNLOXCYT. Checkpoint also reports on clinical data, including longer-term results from its pivotal cosibelimab trial in locally advanced and metastatic cSCC presented at major oncology meetings.
Investors following CKPT can also expect corporate and financial announcements, such as quarterly and full-year financial results, registered direct offerings and warrant exercises, and cash position updates. Strategic developments feature prominently, including the announced Agreement and Plan of Merger with Sun Pharmaceutical Industries, Inc., under which Checkpoint would become a wholly owned subsidiary of Sun Pharma if closing conditions are satisfied.
Additional news coverage highlights scientific and business collaborations, for example Checkpoint’s collaboration with GC Cell to explore the combined therapeutic potential of cosibelimab with Immuncell-LC, an autologous Cytokine Induced Killer T cell therapy. Conference presentations, such as corporate overviews at investor conferences, also appear in the company’s news flow. For investors and observers interested in immuno-oncology, PD-L1–targeting therapies, and EGFR-driven lung cancer research, the CKPT news page offers an ongoing view into Checkpoint’s regulatory, clinical, financial and strategic developments.
Checkpoint Therapeutics (NASDAQ: CKPT) has announced the participation of President and CEO James F. Oliviero in three virtual investor conferences in September 2020. The events include:
- H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 3:30 p.m. EDT
- Cantor Virtual Global Healthcare Conference on September 16, 2020, at 10:00 a.m. EDT
- Lake Street Capital Markets 4th Annual Best Ideas Growth Conference on September 17, 2020
Webcasts will be available on Checkpoint’s website for approximately 30 days post-event.
Checkpoint Therapeutics (NASDAQ: CKPT) reported its Q2 financial results on August 5, 2020.
As of June 30, 2020, the company had cash and cash equivalents of $21.9 million, down from $26.1 million at the end of 2019. R&D expenses decreased to $3.0 million from $4.1 million in 2019.
Despite a net loss of $4.6 million, improving from a loss of $4.8 million in Q2 2019, Checkpoint continues to advance its anti-PD-L1 antibody cosibelimab, with enrollment at over 50% for its pivotal trial in metastatic cutaneous squamous cell carcinoma.
Checkpoint Therapeutics (CKPT) announced updated interim data on cosibelimab for metastatic cutaneous squamous cell carcinoma (mCSCC) ahead of its presentation at the ESMO Virtual Congress 2020. Over 50% of the enrollment target has been achieved, with completion expected by year-end. Cosibelimab, a high-affinity anti-PD-L1 antibody, aims to disrupt the $25 billion PD-(L)1 therapy market with competitive pricing. The company expects to share full top-line results next year for this promising therapy, which currently has a 50% objective response rate among initial patients.
Checkpoint Therapeutics (NASDAQ: CKPT) will host its 2020 Annual Meeting of Stockholders virtually on June 4, 2020, at 10:00 a.m. ET due to COVID-19 concerns. Stockholders of record as of April 7, 2020, can vote and access the meeting online. To participate, stockholders must log in by 9:45 a.m. ET and use their control number from proxy materials. A list of eligible voters will be available for review 10 days prior. Checkpoint focuses on developing treatments for solid tumor cancers, including evaluating its lead products, cosibelimab and CK-101.
Checkpoint Therapeutics, Inc. (CKPT) announced its Q1 2020 financial results, reporting revenue of $1.0 million, a 150% increase year-over-year. The company's cash reserves decreased to $21.5 million from $26.1 million. Research and development expenses were reduced to $2.6 million, down $2.0 million from Q1 2019. General and administrative expenses were stable at $1.7 million. Notably, the FDA confirmed the registration pathway for cosibelimab for treating metastatic cutaneous squamous cell carcinoma, and a patent for cosibelimab was issued, ensuring protection until at least May 2038.